“The findings give patients and their doctors a clearer map of the appropriate post-operative treatment route to follow. Not all patients benefit from chemotherapy after surgery and those with less aggressive cancer may be spared from the potentially debilitating side effects of this treatment,” says principal investigator Dr. Ming Tsao, pathologist at the Princess Margaret Hospital (PMH) Cancer Program, University Health Network (UHN), and Professor of Laboratory Medicine and Pathobiology at the University of Toronto. He also holds the M. Qasim Choksi Chair in Lung Cancer Translational Research at UHN.
“Our study was rigorously validated by multiple testing across data from different patient populations and so we believe these findings can be applied generally to other patients with early-stage non-small cell lung cancer,” says Dr. Tsao.
“The ability to tell whether a particular patient is a good candidate for adjuvant chemotherapy will bring us closer to our goals of improving patient care through personalized medicine,” adds study collaborator Dr. Frances Shepherd, PMH medical oncologist and holder of the Scott Taylor Chair in Lung Cancer Research at UHN.
The study, published online today in the Journal of Clinical Oncology (JCO 64325), advances the 2005 findings of the NCIC Clinical Trials Group study JBR.10, conducted in collaboration with the U.S. National Cancer Institute. The JBR.10 findings showed significant survival benefit from the anti-cancer drugs vinorelbine and cisplatin in patients with early-stage (stage I and II) non-small cell lung cancer whose tumors had been surgically removed. Dr. Tsao’s research team and collaborators at NCIC Clinical Trials Group at Queen’s University performed a genetic analysis of tumor tissue from 133 of the 482 patients from the JBR.10 study who had banked frozen tumor samples.
The Tsao team identified a set of 15 genes that, in 62 patients who did not receive chemotherapy after surgery, predicted which patients had aggressive cancers with high risk of recurrence and death (31 patients), and which had less aggressive disease and low risk of recurrence (31 patients).They then applied the signature to 71 patients who were randomized to receive chemotherapy in the JBR.10 trial. Patients predicted to have aggressive disease
experienced the greatest benefit from chemotherapy — with a 67 percent reduction in the risk of death — while chemotherapy did not reduce the risk of death in patients designated as low risk.
While a previous JBR.10 analysis showed that overall only patients with stage II disease benefited from chemotherapy after surgery, Dr. Tsao’s study demonstrates that the 15 gene signature may identify patients with both stage I and II cancers who may benefit from post-operative chemotherapy.
The research was supported by the Canadian Cancer Society and the National Cancer Institute in the United States. Drs. Tsao and Shepherd, clinician-scientists at the hospital’s research arm, the Ontario Cancer Institute, which includes the Campbell Family Cancer Research Institute, are also supported by the PMH Foundation and the Ontario Ministry of Health and Long-term Care.
Princess Margaret Hospital and its research arm Ontario Cancer Institute, which includes the Campbell Family Cancer Research Institute, have achieved an international reputation as global leaders in the fight against cancer. Princess Margaret Hospital is a member of the University Health Network, which also includes Toronto General Hospital and Toronto Western Hospital. All three are research hospitals affiliated with the University of Toronto. For more information, go to www.uhn.ca
The NCIC Clinical Trials Group (NCIC CTG) is a cancer clinical trials cooperative group that conducts phase I-III trials testing anti-cancer and supportive therapies across Canada and internationally. It is one of the national programmes and networks of the Canadian Cancer Society Research Institute (CCSRI), and is supported by the CCSRI with funds raised by the Canadian Cancer Society (CCS). The NCIC CTG’s Central Office is located at Queen’s University in Kingston, Ontario, Canada.
Jane Finlayson | Newswise Science News
A Map of the Cell’s Power Station
18.08.2017 | Albert-Ludwigs-Universität Freiburg im Breisgau
On the way to developing a new active ingredient against chronic infections
21.08.2017 | Deutsches Zentrum für Infektionsforschung
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
21.08.2017 | Life Sciences
21.08.2017 | Information Technology
18.08.2017 | Life Sciences